The top documents tagged [discontinued treatment]

Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study
Documents Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study

220 views

Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D.,
Documents Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D.,

215 views

how_long_do_treatment_effects_last._persistence_and_durability_of_a_descriptive_norms_interventions_effect_on_energy_conservation.pdf
Documents how_long_do_treatment_effects_last._persistence_and_durability_of_a_descriptive_norms_interventions_effect_on_energy_conservation.pdf

212 views

TREATMENT NON-COMPLIANCE IN PSYCHIATRY. NON-COMPLIANCE: PREVALENCE REASONS CLINICAL CONSEQUENCES - Dr. Ashish Srivastava, M.D
Documents TREATMENT NON-COMPLIANCE IN PSYCHIATRY. NON-COMPLIANCE: PREVALENCE REASONS CLINICAL CONSEQUENCES - Dr. Ashish Srivastava, M.D

215 views

Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for
Documents Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for

217 views

PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing
Documents PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing

216 views

Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A
Documents Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A

216 views

Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD
Documents Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD

34 views

2 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts
Documents 2 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts

217 views

Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for
Documents Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for

225 views

Background
Documents Background

32 views

Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees
Documents Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees

53 views